Opko Health Inc (OPK)

Healthcare Diagnostics & Research

1.30 $

-1.1% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Opko Health Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Momentum & Trend

Stan Weinstein: Stage 3

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap

1.0$B

Shares Outstanding

755Mio.

Float

44.1%

Beta

1.5

Performance

Perf. 1M

5.60%

Perf. 3M

34.80%

Perf. 6M

16.20%

YTD Performance (%)

15.90%

52-Week-High Distance

-5.6%

Perf. 1Y

17.32%

Perf. 3Y

-8.80%

Perf. 5Y

-60.48%

Valuation

P/E

–

Forward P/E

53.8

PEG

93.6

P/B

0.8

P/S

1.6

EV/EBITDA

19.9

Price/FCF

–

Profitability

Gross Margin

14.9%

EBIT Margin

–

Net Margin

-36.6%

Return on Equity

-16.9%

Return on Assets

-6.4%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

0.3

Altman Z″

1.99

Piotroski

4 out of 9

Growth

Sales Growth Last Quarter

-17.20%

EPS Growth Last Quarter

-12.60%

Sales Growth (Year)

-14.90%

Forward Sales Growth

5.55%

Forward EPS Growth

15.80%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

4 out of 9

Fundamental Rating

D (37 out of 100)

Altman Z″

1.99

AI Rating

Neutral

Geprüft am 13.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 26.02.2026) und 2024 (03.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q, bis 31.03.2026). In den ausgewerteten SEC-Filings von OPKO Health findet sich kein wesentlicher KI-Bezug: keine KI-Umsatzquelle (das Geschäft besteht aus Wachstumshormon NGENLA über Pfizer, Rayaldee, der Biotech-Pipeline ModeX sowie dem Labor BioReference), kein dokumentierter operativer KI-Einsatz und kein konkretes KI-Geschäftsrisiko für das eigene Modell. Die einzige Erwähnung von „artificial intelligence“ steht in der Cybersecurity-Darstellung (Item 1C) des 10-K 2025 als generische Floskel, wonach Angreifer KI nutzen könnten, um Cyberattacken wirksamer zu machen — laut Kriterienkatalog kein Bedroht-Beleg (Boilerplate-Risk-Floskel ohne konkreten Bezug zum Geschäftsmodell). Nach der Vorrang-Regel (verkauft > bedroht > nutzt > neutral) bleibt es damit dokumentiert bei „neutral“. Die vier jüngsten 10-Q enthalten gar keine KI-Treffer.

View the full file — quotes, sources, reviewed filings

„Such attacks also may be further enhanced in frequency or effectiveness through threat actors' use of artificial intelligence ("AI")."

Solche Angriffe können zudem in Häufigkeit oder Wirksamkeit durch den Einsatz künstlicher Intelligenz („KI“) durch die Angreifer verstärkt werden.

10-K · 2026-02-26 · View SEC filing

„As with many innovations, AI presents risks, challenges, and unintended consequences that could affect its adoption, and therefore our business. AI algorithms and training methodologies may be flawed, ineffective or inadequate."

Wie bei vielen Innovationen birgt KI Risiken, Herausforderungen und unbeabsichtigte Folgen, die ihre Verbreitung und damit unser Geschäft beeinflussen könnten. KI-Algorithmen und Trainingsmethoden können fehlerhaft, unwirksam oder unzureichend sein.

10-K · 2026-02-26 · View SEC filing

Filings Reviewed: 10-Q 2026-04-28 · 10-Q 2025-10-29 · 10-Q 2025-07-31 · 10-Q 2025-05-01 · 10-K 2026-02-26 · 10-K 2025-03-03

Rated on July 13, 2026 · How the Rating Is Built

Analysts & Price Target

Current Price 1.30 $

Price Target (average) 4.38 $

The price target sits 236.9% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Sales Per Quarter ($M)

Earnings Per Share Per Quarter ($)

Net Margin Per Quarter (%)

Operating Cash Flow Per Quarter ($M)

Free Cash Flow Per Quarter ($M)

Sales Growth vs. Year-Ago Quarter (%)

EPS Growth vs. Year-Ago Quarter (%)

Price Change in Quarter (%)

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	0.02	–	184	1.00	7.60	-44	-50
2025: Q1	-0.10	–	150	-13.70	-45.10	-35	-38
2025: Q2	-0.19	–	157	-13.90	-94.70	-83	-87
2025: Q3	0.03	-22.50	152	-12.60	14.30	-35	-38
2025: Q4	-0.04	-302.00	148	-19.20	-21.10	-26	-29
2026: Q1	-0.07	–	124	-17.20	-44.20	-19	-21
2026: Q2	-0.01	94.70	164	4.30	-5.10	-44	-44

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

OPKO Health, Inc. ist ein Gesundheitsunternehmen in den USA, Irland, Chile, Spanien, Israel, Mexiko und international.

Employees	2,275
Headquarters	Miami, FL
Website	opko.com
IPO Date	2. Nov 1995

Management

Management
Name	Title	Birth Year
Phillip Frost M.D., Ph.D.	Chairman of the Board & CEO	1936
Jane H. Hsiao M.B.A., Ph.D.	Vice Chairman of the Board & Chief Technical Officer	1947
Elias Adam Zerhouni M.D.	President & Vice Chairman of the Board	1951
Adam E. Logal	Senior VP, CFO, Chief Accounting Officer & Treasurer	1978
Steven D. Rubin Esq., J.D.	Executive VP of Administration & Director	1960
Akhtar Ashfaq FACP, FASN, M.D.	Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal	–
Gary J. Nabel M.D., Ph.D.	Chief Innovation Officer & Director	1954
Giovanni Abbadessa M.D., Ph.D.	Chief Medical Officer of ModeX	–
John R. Mascola M.D.	Chief Scientific Officer of ModeX	–
Charles W. Bishop Ph.D.	Chief Executive Officer of OPKO Renal	1952

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date	Person	Role	Type	Shares	Price	Value
24. Jul 2026	Logal Adam	Sr. Vice President, CFO	Other	53,266	1.22	64,985
24. Jul 2026	Rubin Steven D	Executive VP-Administration	Other	53,266	1.22	64,985

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.